0.7951
price up icon4.58%   0.0348
after-market Handel nachbörslich: .78 -0.0151 -1.90%
loading
Schlusskurs vom Vortag:
$0.7603
Offen:
$0.7603
24-Stunden-Volumen:
1.27M
Relative Volume:
0.78
Marktkapitalisierung:
$93.31M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.3058
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+10.28%
1M Leistung:
+3.80%
6M Leistung:
-43.21%
1J Leistung:
-42.80%
1-Tages-Spanne:
Value
$0.752
$0.7985
1-Wochen-Bereich:
Value
$0.72
$0.7985
52-Wochen-Spanne:
Value
$0.6603
$2.43

Coherus Oncology Inc Stock (CHRS) Company Profile

Name
Firmenname
Coherus Oncology Inc
Name
Telefon
(650) 649-3530
Name
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Name
Mitarbeiter
221
Name
Twitter
@coherus_bio
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
CHRS's Discussions on Twitter

Vergleichen Sie CHRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CHRS
Coherus Oncology Inc
0.7951 93.31M 257.24M -237.89M -175.17M -2.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-16 Herabstufung UBS Buy → Neutral
2023-11-17 Eingeleitet Robert W. Baird Outperform
2023-11-08 Herabstufung Maxim Group Buy → Hold
2023-07-24 Eingeleitet Citigroup Buy
2023-05-01 Eingeleitet Truist Buy
2023-03-28 Hochstufung UBS Neutral → Buy
2022-06-14 Eingeleitet UBS Neutral
2022-03-07 Herabstufung JP Morgan Overweight → Neutral
2020-07-16 Eingeleitet BofA Securities Neutral
2020-04-17 Eingeleitet SunTrust Buy
2019-08-13 Eingeleitet Mizuho Buy
2019-08-02 Bestätigt H.C. Wainwright Buy
2019-08-02 Bestätigt Maxim Group Buy
2019-06-11 Eingeleitet Barclays Overweight
2019-05-07 Eingeleitet H.C. Wainwright Buy
2018-08-28 Eingeleitet H.C. Wainwright Buy
2018-03-09 Bestätigt Maxim Group Buy
2017-08-08 Bestätigt JP Morgan Overweight
2017-06-13 Bestätigt Maxim Group Buy
2017-05-05 Eingeleitet BMO Capital Markets Outperform
2016-10-19 Eingeleitet Robert W. Baird Outperform
2016-09-07 Eingeleitet Maxim Group Buy
2016-07-27 Eingeleitet Citigroup Buy
2016-01-20 Eingeleitet Credit Suisse Outperform
Alle ansehen

Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten

pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 06, 2025

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey

Jun 06, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
May 31, 2025

Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World

May 31, 2025
pulisher
May 30, 2025

Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Biosciences Rebrands to Coherus Oncology - TipRanks

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan

May 30, 2025
pulisher
May 30, 2025

Coherus Oncology (CHRS) Shifts Focus with New Name and Innovative Therapies | CHRS Stock News - GuruFocus

May 30, 2025
pulisher
May 28, 2025

First patient dosed in STORM-Coherus cancer alliance - Business Weekly

May 28, 2025
pulisher
May 27, 2025

Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com

May 22, 2025
pulisher
May 20, 2025

StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World

May 20, 2025
pulisher
May 20, 2025

The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

May 20, 2025
pulisher
May 18, 2025

Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks

May 15, 2025
pulisher
May 15, 2025

Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st

May 15, 2025
pulisher
May 14, 2025

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks

May 13, 2025
pulisher
May 12, 2025

Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq

May 12, 2025

Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):